Citadel Advisors - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 41 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$41,921
-89.6%
209,500
+6.8%
0.00%
Q2 2023$404,082
-39.1%
196,156
-2.5%
0.00%
Q1 2023$663,854
+127.2%
201,168
+12.9%
0.00%
Q4 2022$292,189
-58.2%
178,164
+12.6%
0.00%
Q3 2022$699,000
+82.0%
158,207
+13.5%
0.00%
Q2 2022$384,000
-4.0%
139,385
+17.0%
0.00%
Q1 2022$400,000
-50.7%
119,119
-41.3%
0.00%
Q4 2021$812,000
+11.7%
203,000
-7.8%
0.00%
Q3 2021$727,000
-36.5%
220,280
-26.8%
0.00%
Q2 2021$1,144,000
-10.6%
300,867
-10.0%
0.00%
Q1 2021$1,280,000
-5.6%
334,354
+11.6%
0.00%
Q4 2020$1,356,000
-75.3%
299,600
-7.8%
0.00%
-100.0%
Q3 2020$5,499,000
+117.9%
325,000
+44.4%
0.00%0.0%
Q2 2020$2,524,000
+295.6%
225,100
+63.6%
0.00%
Q1 2020$638,000
+188.7%
137,600
+165.9%
0.00%
Q4 2019$221,000
+40.8%
51,740
+29.6%
0.00%
Q2 2019$157,000
+1.3%
39,914
+11.8%
0.00%
Q1 2019$155,000
+297.4%
35,711
+228.6%
0.00%
Q4 2018$39,000
-62.5%
10,867
-60.3%
0.00%
Q3 2018$104,000
+8.3%
27,400
+11.8%
0.00%
Q2 2018$96,000
+62.7%
24,500
+63.0%
0.00%
Q4 2017$59,000
-43.8%
15,034
-41.3%
0.00%
Q3 2017$105,000
-21.6%
25,598
-20.3%
0.00%
Q2 2017$134,000
+81.1%
32,100
+84.8%
0.00%
Q1 2017$74,000
+131.2%
17,372
+45.4%
0.00%
Q1 2016$32,00011,9480.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q1 2022
NameSharesValueWeighting ↓
Weaver Consulting Group 130,000$437,0000.21%
Ikarian Capital, LLC 304,161$1,022,0000.13%
ABNER HERRMAN & BROCK LLC 265,000$890,0000.12%
S.C. Financial Services, Inc. 15,285$51,0000.06%
JMAC ENTERPRISES LLC 45,430$153,0000.04%
CFO4Life Group, LLC 12,000$40,0000.01%
OSAIC HOLDINGS, INC. 10,839$1,329,0000.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$10,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 29,186$98,0000.00%
RAYMOND JAMES & ASSOCIATES 190,403$640,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders